ABL is focused on accelerating your viral vector therapy breakthrough to get it in the hands of those who need it sooner.
As viral vector experts, we optimize the development and manufacturing of preclinical and clinical virus-based biologics, including lentivirus. The result is a linearly scaled, repeatable, and robust process.
With ABL as your strategic partner, your life-changing innovation can be scaled in as quickly as a few months.
ABL has refined the process of harvesting sensitive lentivirus to both an art form and proven science. By using iCELLis® bioreactor technology, we’re able to rapidly scale-up clinical-grade lentivirus material in a fraction of the time.
Isabelle Pelletier
ABL, Senior Staff Scientist
